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We present our surgical experiences with functioning
neuroendocrine neoplasms of the pancreas to define its natural
history, and to suggest its proper management. From June 1990
to June 2005, patients with diagnosis of functioning neuro-
endocrine (islet cell) neoplasms of the pancreas were retro-
spectively reviewed. Fourteen patients (5 men and 9 women)
with a median age of 49 years (range, 12 - 68 years) were
identified. Twelve patients (86%) had insulinoma, two (14%)
had gastrinoma. One (7%) with pancreatic insulinoma was
multiple endocrine neoplasia type 1. Intraoperative ultrasound
scan (sensitivity, 83%) was the most powerful modality for
tumor localization. Fifteen neoplasms with median tumor size
1 cm (range 0-3 cm) were resected. Four insulinomas (26.7%)
were located in the head of the pancreas and 5 (36%), in the
tail. Another 5 (36%) insulinomas and 1 (7%) gastrinoma were
located around the neck area near the SMV or PV. Eleven
patients (79%) underwent enucleation, and 2 patients (14%),
distal pancreatectomy with splenectomy. 100% of patients
with functioning neuroendocrine neoplasms of the pancreas
have survived. The overall disease free 10-year survival was
found to be about 81%. Exact localization of tumor by
intraoperative ultrasound and surgical removal are promising
for good prognosis.
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INTRODUCTION
An islet cell neoplasm of the pancreas is a rare
pathologic condition. An annual incidence of 5 to
10 patients per million is reported.1 This patho-
logic entity can be divided into "nonfunctioning"
and "functioning" neuroendocrine neoplasms of
the pancreas according to the tumor's ability to
produce pancreatic neuroendocrine hormones,
such as, gastrin, insulin, glucagon, somatostatin,
and vasoactive intestinal peptide (VIP). This can
result in clinical or laboratory serum evidence of
neuroendocrine hormone hypersecretion.
Patients with a functioning neuroendocrine
neoplasm of the pancreas have characteristic
symptoms caused by tumor specific pancreatic
neuroendocrine hormones. However, the rarity of
these pathologic conditions makes it difficult to
recognize even a functioning neuroendocrine neo-
plasm of the pancreas,2,3 as a result, can lead to
delayed in definitive treatment.
The purpose of this study is to review our
surgical experiences with functioning neuroen-
docrine neoplasms of the pancreas. This study
focuses on insulinoma, including its clinical
presentation, operative management, and peri-
operative outcomes of patients who underwent
surgery for functioning neuroendocrine tumors of
the pancreas.
MATERIALS AND METHODS
A retrospective review of the medical records of
patients with a functioning neuroendocrine neo-
plasm of the pancreas was performed in Yonsei
University Medical Center (academic tertiary care
referral center), Seoul, Korea. From June 1990 to
June 2005, the medical records of all patients with
a functioning neuroendocrine tumor of the pan-
creas were retrospectively reviewed to identify
patients' characteristics, clinical presentation,
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radiographic localization, operative methods,
operative morbidity, tumor characteristics, and
prognosis. The diagnosis of a functioning neuro-
endocrine tumor of the pancreas was based on
clinical and histopathologic characteristics. A
characteristic clinical syndrome of excessive
neuroendocrine hormone, as well as histologic
and immunohistochemical confirmation of a pan-
creatic islet-cell neoplasm, were needed for
definitive diagnosis. Perioperative serum levels of
neuroendocrine hormones were recorded.
Statistics were applied as appropriate to the data.
All times were reported in months and survival
time was calculated from the date of treatment to
a specified end point, for example, death or date
of last follow-up. Follow-up was obtained through
medical records, telephone contact and personal
data provided by official records and was com-
plete as of August 30, 2005.
RESULTS
Patient characteristics
Fourteen patients who had diagnosis of func-
tioning NENs of pancreas and underwent surgery
were identified. There were 5 men and 9 women
with a median age of 49 years (range 12-68).
Twelve out of 14 (86%) patients had insulinoma,
and the other two patients (14%) had gastrinoma.
One patient (7%) with pancreatic insulinoma had
MEN 1.
Clinical presentations
All patients presented with signs and symptoms
of specific hormonal excess (Table 1). All 12 patients
with insulinoma presented with Whipples's triad.
They showed clinical symptoms and signs of
hypoglycemia, median blood glucose less than 40
mg/dL, and relief of symptoms with glucose
administration. Both two cases of gastrinoma
presented with peptic ulcer disease for which they
had already undergone peptic ulcer surgery, such
as antrectomy and gastrojejunostomy with truncal
vagotomy, more than 10 years ago. Endoscopic
gastroduodenoscopy revealed multiple jejunal
ulcerative lesions. However, they did not present
with typical diarrhea caused by excessive gastric
secretion which is normally stopped by applying
nasogastric drainage. Median period from initia-
tion of symptoms to the definitive treatment was
9 months (range 0.5 - 240 month).
Predicting tumor localization
The most powerful radiological modality for
tumor localization was the intraoperative ultra-
sound scan (sensitivity, 83%), followed by the
endoscopic ultrasound scan (67%), and then the
transhepatic portal venous sampling (63%) (Table
2).
Table 1. Hormonal Evaluation on Presentation
Median (range) Reference range
Insulinoma (n = 12)
Insulin (mU/mL) 28.3 (15.1 - 97.3) 3 - 12
C-peptide (ng/mL) 3.5 (2.06 - 7.63) 1 - 3.5
Glucose (mg/dL) 38.0 (28 - 55.0) 70 - 110
Insulin/Glucose 0.74 (0.4 - 2.6) > 0.4
Gastrinoma (n = 2)
Gastrin (pg/mL) > 1000 0 - 90
Table 2. Diagnostic Accuracy of Preoperative Tumor
Localization
Frequency Localization %
US 9 3 33.3
EUS 6 4 66.6
CT 14 8 57.1
MRI 3 1 33.3
ERCP 2 1 50.0
Arteriography 6 2 33.3
IOUS 6 5 83.3
THPVS/Ca++
stimulation test
8 5 62.5
US, ultrasound scan; EUS, endoscopic ultrasound scan; CT,
computed tomography; MRI, magnetic resonance image; ERCP,
endoscopic retrograde cholangiopancreatography; IOUS, Intra-
operartive ultrasounds scan; THPVS, transhepatic portal vein
sampling
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Tumor characteristics
Fifteen neoplasms were found among surgically
resectable 13 patients. The median tumor size was
1 cm (range 0-3 cm) in diameter. Four insulinomas
were located in the head of the pancreas and
additional 5 (36%), in the tail. Another 5 insu-
linomas (36%) and 1 (7%) gastrinoma were located
around the neck area near the SMV or PV (Fig.
1).
Three patients (21%) had multiple neuroendo-
crine tumors. Two patients with insulinoma had
two discrete tumors in the head and neck,
respectively. One of them was discovered during
the second operation for recurred hypoglycemic
symptoms after the first surgery. One patient with
gastrinoma who had hepatic metastases had
multiple masses in the pancreas and duodenum.
A malignant tumor was discovered in 2 patients
(14%). One patient had multiple metastatic gas-
trinomas, and another patient had an insulinoma
with local invasion on permanent pathologic
report.
Operative procedure
The enucleation of tumors was the most com-
mon procedure for the treatment of functioning
neuroendocrine neoplasms of the pancreas. Eleven
patients (79%) underwent enucleation, and 2
patients (14%) underwent distal pancreatectomy
with splenectomy. A laparoscopic distal pan-
createctomy with splenectomy was performed in
one of them. One patient with multiple metastatic
gastrinomas did not receive operation.
There were 2 cases (14.3%) of re-operation in
functioning neuroendocrine reoperations of the
pancreas. One patient underwent distal pan-
createctomy with splenectomy after enucleation of
the insulinoma, because the permanent pathologic
section showed peripancreatic tissue invasion of
the tumor, a malignant feature. The other patient
underwent transection of the neck of the pancreas
and wedge resection of the pancreas with Roux-
en-y pancreaticojejunostomy due to a recurred
functioning insulinoma after enucleation of the
primary neoplasm.
Postoperative complications
Four patients (30.8%) experienced postoperative
complications after surgery. They were focal
pancreatitis (1), pleural effusion (1), postoperative
ileus (1), and wound problem (1). All were suc-
cessfully managed by conservative management.
Prognosis and long term follow up
All patients of functioning neuroendocrine
tumors survived except 1 patient with insulinoma.
This patient died of an acute myocardial infarction
which is not believed to be related to insulinoma
70 months after surgery. Therefore, statistically
100% of patients with functioning neuroendocrine
neoplasms of the pancreas have survived ac-
cording to survival analysis. Two patients (15.4%,
2/13 patients), among those who underwent
surgery for functioning neuroendocrine neo-
plasms of the pancreas, developed recurrence of
clinical symptoms of functioning neuroendocirne
neoplasm (Table 3). Both patients had insulinoma.
One patient is suspected to have MEN I, and the
other patient is suffering from typical hypogly-
cemic symptoms, approximately 96 months after
surgery. The latter case has been managed conser-
vatively by ingesting sugar containing food early
every morning. The overall disease free 10-year
survival was found to be about 81% with a mean
Fig. 1. Distribution of functioning neuroendocrine neo-
plasm of the pancreas.
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disease free survival of 164 months (95% con
fidence interval, 133.14-191.78 months)(Fig. 2).
One patient with gastrinoma had serum gastrin
levels around 800 pg/mL without evidence of
tumor recurrence on image study. It is believed
to be derived from a previous vagotomy and a
proton pump inhibitor the patient has been
taking.
DISCUSSION
Neuroendocrine neoplasms of the pancreas are
uncommon. During the last 15 years, we have
experienced only 14 patients with functioning
neuroendocrine neoplasms of the pancreas. In
1998, Johns Hopkins reported their 47-year experi-
ence of patients with pancreatic neuroendocrine
neoplasms.4 According to this paper, it was also
about one patient per year for a total of 58 patients.
Another report on experience with functioning
neuroendocrine neoplasms of the pancreas3 shows
a series of 20 surgically-treated patients with
functional neuroendocrine tumors over 25 years.
This explains less than one patient per year is
treated in a busy academic center. The number of
present patients is still small for a single center.
However, experiences of 14 patients with func-
tioning neuroendocrine neoplasms during the last
15 years are not insignificant.
This rarity of disease must be a major challenge
to alert physician for their recognition and
requirements of treatment Unlike our expectation
that early detection of functioning neuroendocine
neoplasm of the pancreas is possible due to tumor
Fig. 2. Disease free survival of functioning neuroendocrine
tumor of pancreas.
Table 3. Results of Long Term Follow-Up (Median Follow Up Period, 102 Month, Follow Up Rate = 100%)
No. Gender/Age (yrs) Diagnosis Disease status Follow-up (month) Survival
1 M/12 Insulinoma Free of disease 185 Alive
2 M/57 Insulinoma Free of disease 170 Alive
3 F/35 Insulinoma Free of disease 153 Alive
4 F/44 Insulinoma Free of disease 147 Alive
5 F/68 Insulinoma Free of disease 141 Alive
6 F/46 Insulinoma Recurrence 117 Alive
7 F/48 Insulinoma Free of disease 106 Alive
8 M/16 Insulinoma Free of disease 74 Alive
9 F/62 Insulinoma Free of disease 98 Alive
10 M/50 Insulinoma Free of disease 69 Alive
11 F/63 Insulinoma Free of disease 70 Dead (MI)
12 M/60 Gastrinoma Free of disease 52 Alive
13 F/28 Insulinoma Recurrence (MEN I) 30 Alive
14 F/63 Gastrinoma Metastasis 16 Alive
MEN 1, multiple endocrine neoplasia type 1; MI, myocardiac infaction.
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specific syndrome caused by excessive hormonal
secretion, the symptom complexes of functioning
pancreatic neuroendocrine neoplasm are often
initially unrecognized as a result of the rarity of
these tumors. According to our results, the
median time taken from initial symptoms of hor-
monal excess to definitive treatment was 9 months
(range 0.5-240 months). Even in the case of insu-
linomas, all patients experienced intermittent
hypoglycemic symptoms. However, the symp-
tomatic relief after having sugar containing diet or
their ignorance of their symptoms caused delays
in proper management, as well as delayed diag-
nosis. In addition, all the patients with gastrinoma
underwent surgery for peptic ulcers. Patients and
physicians regarded patients' symptoms of
epigastric pain as being derived from previous
peptic ulcer disease caused by incomplete ulcer
surgery.
Preoperative tumor localization of functioning
neuroendocrine neoplasms is very important.
Functioning neuroendocrine neoplasms, such as
insulinoma and gastrinoma, are generally small
tumors with a diameter of less than 1 cm. Com-
puted tomography (CT) or occasionally magnetic
resonance imaging (MRI) are routinely performed
in preoperative investigation for detecting distant
metastasis, lymph node metastasis, local inva-
siveness, as well as tumor location. However, they
have low sensitivity for detecting small func-
tioning neuroendocrine neoplasms of the pan-
creas.5 Our data shows low sensitivity for
detecting tumors of US, CT, and MRI. Occasio-
nally, tumors can be large enough to be detected
in those radiological modalities, however, most
functioning neuroendocrine neoplasms of the
pancreas are not.
The endoscopic ultrasound scan (EUS) has
appeared to be the most efficient method in recent
reports. It shows nearly 90% sensitivity for
visualization of insulinomas.6,7 The disadvantages
of this method can be so operator dependent. In
our result, 66.6% sensitivity was noted in de-
tecting tumors preoperatively. Emergence of the
intra-operative ultrasound (IOUS) has been monu-
mentally important in the treatment of func-
tioning neuroendocrine neoplasms. IOUS has
often been considered essential for performing
surgery in the treatment of neuroendocrine neo-
plasms of the pancreas. Our data shows more
than 83% sensitivity in detecting functioning small
tumors of the pancreas by IOUS. However, it is
necessary that IOUS be done by experienced
investigators. It can identify tumors as small as 3
mm with special sensitivity for insulinomas. In
addition, patients will undergo surgery without
any further localization, relying on total pan-
creatic exploration with palpation and IOUS
investigation.8 The IOUS is especially useful for
the detection of an unexpected insulinoma in
patients with multiple insulinomas. The IOUS
provided sufficient information of tumor location
in a case of recurrence after enucleation of the
insulinoma and unexpected functioning neuro-
endocrine neoplasm was detected
Percutaneous transhepatic portal venous
sampling and selective arterial stimulation can
also be of great help in the detection of func-
tioning neuroendocrine neoplasms of the pan-
creas. However, these investigative tools are
technically difficult and invasive. Therefore, they
are not used as frequently as in the past. If other
preoperative radiological modalities provide
insufficient clues for tumor localization, especially
in cases of recurrence after primary surgery, these
alternate techniques would be helpful.
An analysis of several reported series suggests
that gastrinomas, PPomas, and somatostatinomas
show a 75% preference to an anatomic location to
the right of the superior mesenteric arteries in
peripancreatic tissue. In contrast, about 75% of
insulinomas and glucagonomas were located in
the body and tail of the pancreas to the left of the
superior mesenteric artery.9 Our results show that
functioning neuroendocrine neoplasms of the
pancreas, especially insulinomas, were not
uncommonly located in the neck of the pancreas
around the superior mesenteric vein (SMV, 6 out
of 13 tumors, 46.2%). In addition, one case of
recurred insulinoma, which was detected by
IOUS, was located at the neck area, on the right
side of the SMV. We would like to emphasize that
surgeons should investigate the total pancreas
very carefully in the operative field to detect
tumor location. In particular, the neck area of the
pancreas around the SMV needs to be meticu-
lously investigated by palpation or IOUS.
In this review, most functioning neuroendocrine
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neoplasms of the pancreas were safely enucleated
with cautious dissection. Eleven patients (79%)
underwent enucleation, and two patients under-
went distal pancreatectomy with splenectomy
without serious postoperative complications.
Recently, with the advancement of laparoscopic
skill and experience, laparoscopic pancreatic
resections have been attempted with compatible
results.10 In this study, the laparoscopic procedure
was used for one patient who underwent distal
pancreatectomy. With the help of laparoscopic
equipment, such as laparoscopic IOUS, lapa-
roscopic removal of functioning neuroendocrine
neoplasms of the pancreas is expected to increase.
Even robotic surgery in the pancreas is available
in these days.11 In robotic surgery, fine dissection
with a full range of motion of working arms and
excellent vision would be a strong benefit in
performing enucleation of pancreatic tumors.
Our experience with gastrinoma is very limited.
One patient with gastrinoma who underwent
enucleation of the tumor has been followed up for
more than 50 months after surgery. No image
studies or endoscopic gastroduodenoscopy re-
vealed any tumor recurrence or metastasis.
However, serum gastrin level has been recorded
at more than 800 pg/mL. In considering most
gastrinomas are malignant and tumor size is very
small, the patient needs to be followed very
carefully. The patient has been taking proton
pump inhibitors on a regular basis for a long time.
Another patient with gastrinoma who had initial
metastasis and multiple tumors has been alive for
more than 15 months after diagnosis. She refused
to receive further diagnostic evaluation and
treatment. The patient has also been taking oral
proton pump inhibitors and expresses no specific
complications until the end point of this study. As
with this patient, more potent antisecretory medi-
cations, such as proton pump inhibitors, have
diminished the clinical lethality of gastrinomas.
Therefore, total gastrectomies are infrequently
performed. Gastrinomas are always malignant but
have a very variable prognosis. Approximately
one-fourth of gastrinomas have shown markedly
slow progression. Another fourth rapidly pro-
gress. The remaining may be something in
between the two groups.
12
The two cases we ex-
perienced here might be of the slowly progressing
type.
Pancreatic endocrine neoplasms may occur
sporadically or in conjunction with the MEN I
syndrome. MEN I is characterized by tumors of
the parathyroid, pituitary, pancreas, and occa-
sionally the adrenal gland. This syndrome is asso-
ciated genetically with the defect of chromosome
11 and is inherited in an autosomal dominant
fashion. MEN I account for about 20% of patients
with gastrinomas, 4% of those with insulinomas,
and lesser percentages of those with other neuro-
endocrine neoplasms of the pancreas.13 In our
data, one patient with insulinoma (8%, 1/12 insu-
linomas) is suspected to have MEN I syndrome.
This 28-year-old female patient initially under-
went enucleation because of a functioning
insulinoma. After surgery, the symptoms of
insulinoma developed again. CT and MRI scans
revealed multiple hypervascular tumors spread
over the pancreas. Additional glucagon suppres-
sion test, C-peptide suppression test, and long
starvation test proved diagnosis of an insulinoma.
Serum calcium and PTH were elevated. The sesta-
mibi scan show diffuse enlargement of bilateral
parathyroid glands, and Brain CT scans revealed
a 5.9 × 6.1 mm sized pituitary tumor with an
elevated serum level of prolactin. However, her
family members showed no evidence of any
syndrome of MEN I. She has been being fol-
lowed up on an out-patient basis.
We need to keep in mind that it is necessary to
investigate the possibility of MEN I in the case of
gastrinoma which is known as the most common
functioning neuroendocrine neoplasm associated
with MEN I or in case of recurred insulinoma
with multiplicity. Any patients with pancreatic
endocrine neoplasms should have calcium levels
measured to screen for MEN I, because most
(70-90%) MEN I manifest hyperparathyroidism. If
calcium levels are elevated, the parathyroid and
pituitary glands need to be studied. Important
emphasis should be placed on the fact that most
pancreatic endocrine tumors related to MEN I are
multiple and have malignant potential. Gastri-
nomas that developed in patients with MEN I are
usually malignant, as indicated by the presence of
lymph node or distant metastasis. Approximately
10% of insulinomas related to MEN I are
malignant.14
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The neuroendocrine neoplasms of the pancreas
are rare pathologic conditions, which lead to de-
layed diagnosis and treatment even in functioning
pancreatic endocrine neoplasms. Tumor localiza-
tion and proper operative management is
important from a clinical standpoint. Based on our
results, the pancreatic tissue around the SMV
needs to be carefully investigated, especially in
cases of insulinoma. Sometimes the results of
preoperative tumor localization might be nega-
tive. Resection of 80-90% of the pancreas can be
best management in islet cell hyperplasia of the
pancreas.15 Recognition of MEN I is also im-
portant because pancreatic neuroendocrine neo-
plasm related to MEN I can be malignant and
have multiple distributions. The prognosis of
almost every patient with surgery is very good,
except in two cases of recurrence. Careful follow-
up is mandatory in such cases.
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